Evgen Pharma (EVG) Share Price, News & Analysis

Company Overview

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 227,410 shs
• Average Volume: 1.73 million shs
• Market Capitalization: £3.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 6/15/2020
• Today: 5/14/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Financial Services
• Current Symbol: LON:EVG
• CIK: N/A
• Web: evgen.com
• Phone: +44-151-7053532
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£3.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.57%
• Return on Assets: -45.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.39
• Quick Ratio: 23.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 1.71
• Book Value: GBX 1 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 427,350,000
• Free Float: N/A
• Market Cap: £3.42 million
• Optionable: Not Optionable
• Beta: 1.44